Experimental antifungal chemotherapy in granulocytopenic animal models of disseminated candidiasis: approaches to understanding investigational antifungal compounds for patients with neoplastic diseases.
暂无分享,去创建一个
T. Walsh | P. Pizzo | J. Bacher | E. Roilides | J. Lee | C. Lyman | P. Francis
[1] T. Walsh,et al. Continuous intravenous infusion and simultaneous pharmacokinetic monitoring in ambulatory rabbits with a programmable micropump and dual subcutaneous Silastic central venous catheters. , 1992, Laboratory animal science.
[2] E. Anaissie,et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. , 1991, The American journal of medicine.
[3] D. R. Weber,et al. Hepatosplenic candidiasis: successful treatment with fluconazole. , 1991, The American journal of medicine.
[4] T. Walsh,et al. Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis , 1991, Antimicrobial Agents and Chemotherapy.
[5] T. Walsh,et al. Cilofungin (LY121019) shows nonlinear plasma pharmacokinetics and tissue penetration in rabbits , 1990, Antimicrobial Agents and Chemotherapy.
[6] G. Cole,et al. Evaluation of a murine model of hepatic candidiasis , 1990, Journal of clinical microbiology.
[7] J. Peter,et al. SCH-39304 in prevention and treatment of disseminated candidiasis in persistently granulocytopenic rabbits , 1990, Antimicrobial Agents and Chemotherapy.
[8] J. van de Loo,et al. Hepatosplenic candidosis ‐ a late manifestation of Candida septicemia , 1990, Mycoses.
[9] T. Walsh,et al. Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. , 1990, The Journal of infectious diseases.
[10] T. Walsh,et al. Experimental basis for use of fluconazole for preventive or early treatment of disseminated candidiasis in granulocytopenic hosts. , 1990, Reviews of infectious diseases.
[11] D. Loebenberg,et al. Pharmacokinetics and tissue penetration of Sch 39304 in granulocytopenic and nongranulocytopenic rabbits , 1989, Antimicrobial Agents and Chemotherapy.
[12] J. Perfect,et al. Treatment of experimental disseminated candidiasis with cilofungin , 1989, Antimicrobial Agents and Chemotherapy.
[13] H. Chambers,et al. Evaluation of cilofungin (LY121019) for treatment of experimental Candida albicans endocarditis in rabbits , 1989, Antimicrobial Agents and Chemotherapy.
[14] J. Perfect,et al. Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304 , 1989, Antimicrobial Agents and Chemotherapy.
[15] J. Galgiani,et al. In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy , 1989, Antimicrobial Agents and Chemotherapy.
[16] T. Walsh,et al. Pharmacokinetics and tissue penetration of fluconazole in rabbits , 1989, Antimicrobial Agents and Chemotherapy.
[17] R. Fromtling,et al. L-671,329, a new antifungal agent. III. In vitro activity, toxicity and efficacy in comparison to aculeacin. , 1989, The Journal of antibiotics.
[18] F. Odds. Activity of cilofungin (LY121019) against Candida species in vitro. , 1988, The Journal of antimicrobial chemotherapy.
[19] W. Alborn,et al. Anti‐Candida Activity and Toxicology of LY121019, a Novel Semisynthetic Polypeptide Antifungal Antibiotic a , 1988, Annals of the New York Academy of Sciences.
[20] T. Walsh,et al. Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. , 1988, Laboratory animal science.
[21] P. Pizzo,et al. Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia. , 1988, The Journal of infectious diseases.
[22] A. Catanzaro,et al. Fluconazole Penetration into Cerebrospinal Fluid in Humans , 1988, Journal of clinical pharmacology.
[23] M. Saag,et al. Azole antifungal agents: emphasis on new triazoles , 1988, Antimicrobial Agents and Chemotherapy.
[24] C. Taft. Selitrennikoff C P : LY 121019 inhibits Neurospora crassa growth and (1,3)-β-D-glucan synthase , 1988 .
[25] J. Becker,et al. Use of the chitin-synthesis inhibitor nikkomycin to treat disseminated candidiasis in mice. , 1988, The Journal of infectious diseases.
[26] F. Balis,et al. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. , 1988, The Journal of infectious diseases.
[27] T. Shawker,et al. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. , 1988, Annals of internal medicine.
[28] W. Melchinger,et al. Studies on the In Vitro‐Sensitivity of Yeast Strains Isolated from Clinical Specimens to LY 121019, a New Antifungal Agent * , 1987, Mykosen.
[29] L. Frankel,et al. Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Perfect,et al. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis , 1987, Antimicrobial Agents and Chemotherapy.
[31] J. V. van Cutsem,et al. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. , 1987, Reviews of infectious diseases.
[32] P. Pizzo. After empiric therapy: what to do until the granulocyte comes back. , 1987, Reviews of infectious diseases.
[33] J. Perfect,et al. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits , 1986, Antimicrobial Agents and Chemotherapy.
[34] A. Cassone. Cell wall of pathogenic yeasts and implications for antimycotic therapy. , 1986, Drugs under experimental and clinical research.
[35] B. Wong,et al. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. , 1985, Reviews of infectious diseases.
[36] J. Perfect,et al. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. , 1985, The Journal of antimicrobial chemotherapy.
[37] G. Bodey. Candidiasis in cancer patients. , 1984, The American journal of medicine.
[38] S. Thongprasert,et al. Systemic candidiasis in cancer patients. , 1984, The American journal of medicine.
[39] D. Zeckner,et al. In vitro and in vivo anti-Candida activity and toxicology of LY121019. , 1984, The Journal of antibiotics.
[40] E. Hersh,et al. Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. , 1984, The Journal of infectious diseases.
[41] G. Lopez-Berestein,et al. Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. , 1984, Cancer drug delivery.
[42] E. Hersh,et al. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. , 1983, The Journal of infectious diseases.
[43] D. Armstrong,et al. Fever, rash, and myalgias of dissseminated candidiasis during antifungal therapy. , 1981, Archives of internal medicine.
[44] R. Silver,et al. Fever, rash, and muscle tenderness. A distinctive clinical presentation of disseminated candidiasis. , 1978, Archives of internal medicine.